VASOPRESSIN RECEPTOR ANTAGONISTS IN HYPONATREMIA: AN UPDATE
Main Article Content
Abstract
Vasopressin also known as Anti Diuretic hormone acting through V2 receptor is the primary physiologic determinant of the rate of free water excretion. In the last decade, knowledge of vasopressin receptors has increased significantly. Multiple vasopressin receptor antagonists have been developed with differences in their specificity to V2:V1 receptors. These agents have applications in conditions of hypervolemic and euvolemic hyponatremia like the syndrome of inappropriate antidiuretic hormone secretion, congestive heart failure, cirrhosis and perhaps in brain edema following traumatic brain injury. Although V2 receptor antagonist may have a proven role in certain condition, only few drugs are currently available and its use still remains limited.
Article Details
How to Cite
RANA, Shraddha; KHANNA, Apurv.
VASOPRESSIN RECEPTOR ANTAGONISTS IN HYPONATREMIA: AN UPDATE.
Medical Research Archives, [S.l.], v. 5, n. 1, jan. 2017.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/967>. Date accessed: 25 apr. 2024.
Keywords
hyponatremia, vasopressin antagonists, congestive heart failure, cirrhosis, syndrome of inappropriate antidiuretic hormone secretion
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006; 119 (7 Suppl 1):S30–S35
2. Clayton JA, Le Jeune IR, Hall IP. Severe hyponatraemia in medical in-patients: aetiology, assessment and outcome. QJM. 2006; 99:505–511
3. Prevalence of hyponatremia and association with mortality: results from NHANES. Am J Med. 2013 Dec; 126(12):1127-37.e1. doi: 10.1016/j.amjmed.2013.07.021.
4. Nicod P, Waeber B, Bussein JP, Goy JJ, Turini G, Nussberger J, Hofbauer K, Brunner HR: Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am J Cardiol (1985) 55:1043-7
5. Berghmans T, Paesmans M, Body JJ (2000) A prospective study on hyponatraemia in medical cancer patients: Epidemiology, aetiology and differential diagnosis. Support Care Cancer 8(3):192–197
6. J Yoon, SH Ahn, YJ Lee, CM Kim Hyponatremia as an independent prognostic factor in patients with terminal cancer Support Care Cancer (2015) 23: 1735.
7. Bahloul M, Chaari A, Chabchoub I, et al. Outcome analysis and outcome predictors of traumatic head injury in childhood: 2011;4(2):198-206. doi:10.4103/0974-2700.82206.
8. The rate of hyponatremia in neurosurgical patients. and recommendations for the diagnosis and treatment. Zh Vopr Neirokhir Im N N Burdenko. 2016 ;80(1):57-70.
9. Rose BD, Post TW: Hypoosmolal states-hyponatremia. In: Clinical physiology of acid base and electrolyte disorders. Rose BD, Post TW (Eds), McGraw Hill, USA (2001): 696-745
10. Efficacy and Safety of Vasopressin Receptor Antagonists for Euvolemic or Hypervolemic Hyponatremia: A Meta-Analysis.Medicine (Baltimore). 2016 Apr; 95(15):e3310. doi: 10.1097/MD
11. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology. 2008 Jul; 48(1):204-13. doi: 10.1002/hep.22293.
12. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.DOI: 10.1002/jcph.342
13.Nicod P, Waeber B, Bussein JP, Goy JJ, Turini G, Nussberger J, Hofbauer K, Brunner HR: Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am J Cardiol (1985) 55:1043-7.
14. Therapeutic effect of conivaptan bolus dosing in hyponatremic neurosurgical patients. Pharmacotherapy. 2013 Jan; 33(1):51-5. doi: 10.1002/phar.1169
15. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H et al: OPC-41061, a highly patent human vasopressin V2 receptor antagonist: pharmacological profile and aquaretic effect by single and multiple dosing in rats. J Pharmacol Exp Ther (1998) 287:860-7.
16. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C, SALT Investigators Tolvaptan, a selective oral vasopressin V2 receptor antagonist for hyponatremia. N Engl J Med (2006) 355:2099-112.
17. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedburg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized with worsening heart failure: the EVEREST outcome trial JAMA (2007) 297:1319-31.
18. Effectiveness and adverse events of tolvaptan in octogenarians with heart failure. Interim analyses of Samsca Post-Marketing Surveillance in Heart faiLurE (SMILE study). Kinugawa K1, Inomata T, Sato N, Yasuda M, Shimakawa T, Bando K, Mizuguchi K. Int Heart J. 2015;56(2):137-43. doi: 10.1536/ihj.14-332. Epub 2015 Feb
19. Chan PS, Coupet J, Park HC, Lai F, Hartupee D, Cervoni P, Dusza JP, Albright JD Ru X, Mazandarani H, Tanikella T et al: VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist Adv Exp Med Biol (1998) 449:439-43.
20. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW: Aquaretic effects of lixivaptan, an oral, nonpeptide selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and II chronic heart failure patients. J Am Coll Cardiol (2006) 47:1615-21.
21. Wong F, Blei AT, Blendis LM, Thuluvath PJ: A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology (2003) 37:182-91.
22. Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, Bankir L, Pouzet B, Guillon G, Barberis C, Chicot D et al: Characterization of SR 111463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest (1996) 98:2729-38
23. Soupart A, Gross P, Legross JJ, Alfoldi S, Annane D, Heshmati HM, Decaux G. Successful long- term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B) an orally active nonpeptide vasopressin V2 receptor antagonist. Clin J Am Soc Nephrol (2006) 1:1154-60.
24.Ginès P, Wong F, Watson H, Terg R, Bruha R, Zarski JP, Dudley F, NormoCAT Study Investigators Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study.Aliment Pharmacol Ther. 2010 Apr; 31(8):834-45. Epub 2010 Jan 22
25.Wong F, Watson H, Gerbes A, Vilstrup H, Badalamenti S, Bernardi M, Ginès P, Satavaptan Investigators Group. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut. 2012 Jan; 61(1):108-16. Epub 2011 Aug 11.
26. Nakamura S, Itoh S, Fujiki H, Yamamura Y, Mori T. Binding affinities of mozavaptan hydrochloride (OPC-31260) for vasopressin receptors. Jpn Pharmacol Ther (2006) 34:827-34.
27. Saito T, Ishikawa S, Abe K, Kamoi K, Yamada K, Shimizu K, Saruta T, Yoshida S. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) J Clin Endocrinol Metab (1997) 82:1054-7
28. Dahl E, Gluud LL, Kimer N, Krag A. Aliment Pharmacol Ther. 2012 Oct; 36(7):619-26. Epub 2012 Aug 21 .Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia
29. Gines P, Guevara M. Hyponatremia in cirrhosis: Pathogenesis, clinical significance and management. Hepatology.2008;48:1002–10
30. Aditya S, Rattan A. Vaptans: A new option in the management of hyponatremia. International Journal of Applied and Basic Medical Research.2012; 2(2):77-83. doi:10.4103/2229-516X.106347.
31.Tomas Berl, Friederike Quittnat-Pelletier, Joseph G. Verbalis, Robert W. Schrier, Daniel G. Bichet, § John Ouyang, and Frank S. Czerwiec: Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia. J Am Soc Nephrol 21: 705–712, 2010. doi: 10.1681/ASN.2009080857
32.Pang Ps, Konstam MA, Krasa HB, Swedberg K, Zannad F, Blair JE, Zimmer C, Teerlink JR, Maggioni AP, Burnett JC Jr, Grinfeld L et al. Effects of tolvaptan on dyspnea relief from the EVEREST trials. Eur Heart J (2009) 30:2233-40.
33. Gross P, Marczewski T, Herbrig K. The vaptans ante portas: a status report. Nephrol Dial Transplant (2009) 24:1371-
34. Lehrich RW, Greenberg A: When is it appropriate to use vasopressin antagonists. J Am Soc Nephrol (2008) 19:1054-8.
2. Clayton JA, Le Jeune IR, Hall IP. Severe hyponatraemia in medical in-patients: aetiology, assessment and outcome. QJM. 2006; 99:505–511
3. Prevalence of hyponatremia and association with mortality: results from NHANES. Am J Med. 2013 Dec; 126(12):1127-37.e1. doi: 10.1016/j.amjmed.2013.07.021.
4. Nicod P, Waeber B, Bussein JP, Goy JJ, Turini G, Nussberger J, Hofbauer K, Brunner HR: Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am J Cardiol (1985) 55:1043-7
5. Berghmans T, Paesmans M, Body JJ (2000) A prospective study on hyponatraemia in medical cancer patients: Epidemiology, aetiology and differential diagnosis. Support Care Cancer 8(3):192–197
6. J Yoon, SH Ahn, YJ Lee, CM Kim Hyponatremia as an independent prognostic factor in patients with terminal cancer Support Care Cancer (2015) 23: 1735.
7. Bahloul M, Chaari A, Chabchoub I, et al. Outcome analysis and outcome predictors of traumatic head injury in childhood: 2011;4(2):198-206. doi:10.4103/0974-2700.82206.
8. The rate of hyponatremia in neurosurgical patients. and recommendations for the diagnosis and treatment. Zh Vopr Neirokhir Im N N Burdenko. 2016 ;80(1):57-70.
9. Rose BD, Post TW: Hypoosmolal states-hyponatremia. In: Clinical physiology of acid base and electrolyte disorders. Rose BD, Post TW (Eds), McGraw Hill, USA (2001): 696-745
10. Efficacy and Safety of Vasopressin Receptor Antagonists for Euvolemic or Hypervolemic Hyponatremia: A Meta-Analysis.Medicine (Baltimore). 2016 Apr; 95(15):e3310. doi: 10.1097/MD
11. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology. 2008 Jul; 48(1):204-13. doi: 10.1002/hep.22293.
12. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.DOI: 10.1002/jcph.342
13.Nicod P, Waeber B, Bussein JP, Goy JJ, Turini G, Nussberger J, Hofbauer K, Brunner HR: Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am J Cardiol (1985) 55:1043-7.
14. Therapeutic effect of conivaptan bolus dosing in hyponatremic neurosurgical patients. Pharmacotherapy. 2013 Jan; 33(1):51-5. doi: 10.1002/phar.1169
15. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H et al: OPC-41061, a highly patent human vasopressin V2 receptor antagonist: pharmacological profile and aquaretic effect by single and multiple dosing in rats. J Pharmacol Exp Ther (1998) 287:860-7.
16. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C, SALT Investigators Tolvaptan, a selective oral vasopressin V2 receptor antagonist for hyponatremia. N Engl J Med (2006) 355:2099-112.
17. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedburg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized with worsening heart failure: the EVEREST outcome trial JAMA (2007) 297:1319-31.
18. Effectiveness and adverse events of tolvaptan in octogenarians with heart failure. Interim analyses of Samsca Post-Marketing Surveillance in Heart faiLurE (SMILE study). Kinugawa K1, Inomata T, Sato N, Yasuda M, Shimakawa T, Bando K, Mizuguchi K. Int Heart J. 2015;56(2):137-43. doi: 10.1536/ihj.14-332. Epub 2015 Feb
19. Chan PS, Coupet J, Park HC, Lai F, Hartupee D, Cervoni P, Dusza JP, Albright JD Ru X, Mazandarani H, Tanikella T et al: VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist Adv Exp Med Biol (1998) 449:439-43.
20. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW: Aquaretic effects of lixivaptan, an oral, nonpeptide selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and II chronic heart failure patients. J Am Coll Cardiol (2006) 47:1615-21.
21. Wong F, Blei AT, Blendis LM, Thuluvath PJ: A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology (2003) 37:182-91.
22. Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, Bankir L, Pouzet B, Guillon G, Barberis C, Chicot D et al: Characterization of SR 111463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest (1996) 98:2729-38
23. Soupart A, Gross P, Legross JJ, Alfoldi S, Annane D, Heshmati HM, Decaux G. Successful long- term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B) an orally active nonpeptide vasopressin V2 receptor antagonist. Clin J Am Soc Nephrol (2006) 1:1154-60.
24.Ginès P, Wong F, Watson H, Terg R, Bruha R, Zarski JP, Dudley F, NormoCAT Study Investigators Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study.Aliment Pharmacol Ther. 2010 Apr; 31(8):834-45. Epub 2010 Jan 22
25.Wong F, Watson H, Gerbes A, Vilstrup H, Badalamenti S, Bernardi M, Ginès P, Satavaptan Investigators Group. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut. 2012 Jan; 61(1):108-16. Epub 2011 Aug 11.
26. Nakamura S, Itoh S, Fujiki H, Yamamura Y, Mori T. Binding affinities of mozavaptan hydrochloride (OPC-31260) for vasopressin receptors. Jpn Pharmacol Ther (2006) 34:827-34.
27. Saito T, Ishikawa S, Abe K, Kamoi K, Yamada K, Shimizu K, Saruta T, Yoshida S. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) J Clin Endocrinol Metab (1997) 82:1054-7
28. Dahl E, Gluud LL, Kimer N, Krag A. Aliment Pharmacol Ther. 2012 Oct; 36(7):619-26. Epub 2012 Aug 21 .Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia
29. Gines P, Guevara M. Hyponatremia in cirrhosis: Pathogenesis, clinical significance and management. Hepatology.2008;48:1002–10
30. Aditya S, Rattan A. Vaptans: A new option in the management of hyponatremia. International Journal of Applied and Basic Medical Research.2012; 2(2):77-83. doi:10.4103/2229-516X.106347.
31.Tomas Berl, Friederike Quittnat-Pelletier, Joseph G. Verbalis, Robert W. Schrier, Daniel G. Bichet, § John Ouyang, and Frank S. Czerwiec: Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia. J Am Soc Nephrol 21: 705–712, 2010. doi: 10.1681/ASN.2009080857
32.Pang Ps, Konstam MA, Krasa HB, Swedberg K, Zannad F, Blair JE, Zimmer C, Teerlink JR, Maggioni AP, Burnett JC Jr, Grinfeld L et al. Effects of tolvaptan on dyspnea relief from the EVEREST trials. Eur Heart J (2009) 30:2233-40.
33. Gross P, Marczewski T, Herbrig K. The vaptans ante portas: a status report. Nephrol Dial Transplant (2009) 24:1371-
34. Lehrich RW, Greenberg A: When is it appropriate to use vasopressin antagonists. J Am Soc Nephrol (2008) 19:1054-8.